Data is available from an extended treatment study in HBeAg negative patients (NUCAB3017) treated with lamivudine.

Data is available from an extended treatment study in HBeAg negative patients (NUCAB3017) treated with lamivudine.

Following HBeAg seroconversion, serologic response and clinical remission are generally durable after stopping lamivudine.

Therefore, following HBeAg seroconversion, patients should be periodically monitored to determine that serologic and clinical responses are being maintained.

In a retrospective study to determine the factors associated with HBV DNA breakthrough, 159 Asian HBeAg-positive patients were treated with lamivudine and followed up for a median period of almost 30 months.